Melane Sampson, Author at BioTuesdays

Markets

Leerink cuts Clovis Oncology PT to $22 from $30

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

October 31, 2018

Developments

Lobo Cube DNA testing device for safer cannabis use gaining major media attention

An Oct. 26 article on the Washington Post web site discusses job openings in Canada’s legalized cannabis sector, highlighting an Ontario government policy advisor who left his job to join Lobo Genetics as its director...

October 26, 2018

Executive Moves

Breath Therapeutics names Peter Shadday as chief commercial officer

Closely-held Breath Therapeutics appointed Peter Shadday as chief commercial officer to lead the company’s market access activities and product commercialization.

October 17, 2018

Markets

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

October 12, 2018

Developments

CHF Solutions in collaboration with NI Medical on fluid overload

CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...

October 11, 2018

Executive Moves

3DS names Sherif Louis as CEO

3D Signatures (TSX:DXD) appointed Sherif Louis, as the company's chief executive officer.

September 25, 2018

Developments

CellAegis completes enrollment in heart attack study with autoRIC

Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...

September 11, 2018

Feature

Actinium Pharma developing targeted conditioning for bone marrow transplant

By Len Zehr Actinium Pharmaceuticals (NYSE American:ATNM) intends to improve bone marrow transplants (BMT) access and patient outcomes and treat cancers with high unmet medical needs by combining the precision of...

September 11, 2018

Developments

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...

September 6, 2018

Markets

Leerink resumes coverage of ObsEva at OP; PT $25

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

August 15, 2018

Author - Melane Sampson

Leerink cuts Clovis Oncology PT to $22 from $30

Lobo Cube DNA testing device for safer cannabis use gaining major media attention

Breath Therapeutics names Peter Shadday as chief commercial officer

Leerink cuts Immune Design to MP; PT to $3 from $7

CHF Solutions in collaboration with NI Medical on fluid overload

3DS names Sherif Louis as CEO

CellAegis completes enrollment in heart attack study with autoRIC

Actinium Pharma developing targeted conditioning for bone marrow transplant

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Leerink resumes coverage of ObsEva at OP; PT $25

Subscribe